Quick Answer
Genprex, Inc. reported Research And Development Expense of $9.43 million for the year ending 2025.
- Genprex, Inc. showed a decrease of -10.5% in Research And Development Expense from 2024 to 2025.
- This data is from Genprex, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $68.4 thousand | Q2 2017: $105.0 thousand | Q3 2017: $55.5 thousand | Q1 2018: $51.6 thousand | Q2 2018: $113.0 thousand | Q3 2018: $489.7 thousand | Q1 2019: $508.0 thousand | Q2 2019: $502.0 thousand | Q3 2019: $467.3 thousand | Q1 2020: $1.48 million | Q2 2020: $2.16 million | Q3 2020: $1.35 million | Q1 2021: $2.04 million | Q2 2021: $1.53 million | Q3 2021: $1.43 million | Q1 2022: $2.04 million | Q2 2022: $2.93 million | Q3 2022: $3.16 million | Q1 2023: $5.31 million | Q2 2023: $3.98 million | Q3 2023: $4.62 million | Q1 2024: $3.27 million | Q2 2024: $1.67 million | Q3 2024: $2.76 million | Q1 2025: $2.54 million | Q2 2025: $2.50 million | Q3 2025: $2.19 million.
- Over the full 10 years of available data (2016 to 2025), Genprex, Inc.'s Research And Development Expense has grown by 2,556.9%.
- Historical annual values: Fiscal year 2025: $9.43 million | Fiscal year 2024: $10.54 million | Fiscal year 2023: $17.62 million | Fiscal year 2022: $11.51 million | Fiscal year 2021: $8.97 million | Fiscal year 2020: $7.30 million | Fiscal year 2019: $1.97 million | Fiscal year 2018: $971.4 thousand | Fiscal year 2017: $289.9 thousand | Fiscal year 2016: $354.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: